Markets

Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape

Keryx Biopharmaceuticals Inc. ( KERX ) saw a big move last session, as the company's shares fell by nearly 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $13.11 to $14.68 since Jan 6, 2015.

On Jan 20, 2015, the company declared that it initiated an underwritten public offering of its common shares worth $100 million.

The medical company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (0 increases, 1 decrease), and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

KERX currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

A better-ranked stock in the medical sector is Alexion Pharmaceuticals, Inc. ( ALXN ), which currently carries a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

KERYX BIOPHARMA (KERX): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALXN

Other Topics

Investing Stocks